Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Epidemiology of Epstein-Barr Virus infection and Infectious Mononucleosis in the United Kingdom

Ashvin Kuri, View ORCID ProfileBenjamin Meir Jacobs, Nicola Vickaryous, Julia Pakpoor, Jaap Middeldorp, Gavin Giovannoni, Ruth Dobson
doi: https://doi.org/10.1101/2020.01.21.20018317
Ashvin Kuri
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and Queen Mary University of London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Meir Jacobs
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and Queen Mary University of London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin Meir Jacobs
Nicola Vickaryous
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and Queen Mary University of London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Pakpoor
2Unit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaap Middeldorp
3Department of Pathology, VU Medical Center, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gavin Giovannoni
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and Queen Mary University of London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Dobson
1Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and Queen Mary University of London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ruth.dobson{at}qmul.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Epstein-Barr Virus (EBV) is a ubiquitous gamma-herpesvirus with which ∼95% of the healthy population is infected. EBV infection has been implicated in a range of haematological malignancies and autoimmune diseases. Delayed primary EBV infection increases the risk of subsequent complications. Over recent decades, the age of primary EBV infection has become later, largely due to improved sanitation and living conditions.

Methods and findings First, we conducted a sero-epidemiological survey of healthy volunteers between 0 and 25 years old to assess prevalence of detectable anti-EBV antibodies. 1982 of 2325 individuals (85.3%) were EBV seropositive. EBV seropositivity increased monotonically with age, and increased more among females than males during adolescence (ages 10 – 15). Second, we conducted a retrospective review of Hospital Episode Statistics to determine changes in Infectious Mononucleosis (IM) incidence over time. Between 2002 and 2013, the incidence of IM (derived from hospital admissions data) increased. We then conducted a large case-control study of 6306 prevalent IM cases and 1,009,971 unmatched controls extracted from an East London GP database to determine exposures associated with IM. Exposures associated with lower risk of IM were elevated BMI (Overweight OR 0.80 [0.75 to 0.86], obese OR 0.63 [0.57 to 0.70]), non-white ethnicity (Black OR 0.21 [0.18 to 0.23], Asian OR 0.14 [0.13 to 0.16], Other ethnicity OR 0.22 [0.19 to 0.25]), and a history of smoking (OR 0.87 [0.83 to 0.92]), whereas affluence was associated with a higher risk of IM (per increase in IMD decile OR 1.15 [1.13 to 1.17]. Finally, we used ELISA to determine antibody responses to common pathogens and vaccine antigens among EBV-seronegative individuals. EBV-seronegative donors did not display diminished serum antibody responses to pertussis, rubella, or varicella compared to EBV-seropositive donors.

Conclusions In this study we make several important observations on the epidemiology of EBV infection in the UK. We find that overall EBV seroprevalence in the UK appears to have increased, and that the sharp increase in EBV seropositivity takes places earlier among females than males. We find that the incidence of IM requiring hospitalisation is increasing. We find that exposures associated with prevalent IM in a diverse population include white ethnicity, affluence, lower BMI, and never-smoking, and these exposures interact with each other. Lastly, we provide pilot evidence suggesting that antibody responses to vaccine and encountered pathogens do not seem to be diminished among EBV-seronegative individuals, which is a theoretical counter-argument to developing EBV vaccines. Our findings could help to inform vaccine study designs in efforts to prevent IM and late complications of EBV infection, such as Multiple Sclerosis.

Key messages

  • - Epstein-Barr Virus (EBV) is a ubiquitous virus which infects over 95% of the world’s population. The majority of infection is silent and without consequence. In a subset of individuals, EBV is thought to play a role in the pathogenesis of autoimmune disease and haematological cancers.

  • - During childhood and adolescence, EBV seroprevalence increased monotonically with age from 0-5 (67.8% females, 72.0% males) to 20-25 (96.4% females, 95.5% males)

  • - The incidence of Infectious Mononucleosis (IM) leading to hospital admission has increased over the past decade

  • - Exposure associated with IM in a large, diverse East London cohort (n>1,000,000) were low BMI, never-smoking, white ethnicity, and affluence.

Competing Interest Statement

RD: Honoraria for speaking or other educational activities: Biogen, Merck, Teva Support to attend educational meeting: Sanofi Honoraria for advisory board: Merck, Biogen Research support: Biogen, Merck, Celgene JM is CEO at Cyto-Barr BV. GG: I have received research grant support from Bayer-Schering Healthcare, Biogen-Idec, GW Pharma, Merck, Merck-Serono, Merz, Novartis, Teva and Sanofi-Aventis. I have also received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Bayer-Schering Healthcare, Biogen-Idec, Canbex, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, Ironwood, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals. JP: Served on an advisory board for Merck Serono

Funding Statement

We are grateful to Barts Charity for supporting this work, to the SEU for providing sera, to Jaap Middeldorp for providing anonymised EBV-seronegative sera, to Mark Jitlal for his help in data extraction from the ELGP database, and to all the volunteers and patients who have provided their data for the study.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* joint first authors

  • Competing interests: RD:

    Honoraria for speaking or other educational activities: Biogen, Merck, Teva

    Support to attend educational meeting: Sanofi

    Honoraria for advisory board: Merck, Biogen

    Research support: Biogen, Merck, Celgene

    JM is CEO at Cyto-Barr BV.

    GG: I have received research grant support from Bayer-Schering Healthcare, Biogen-Idec, GW Pharma, Merck, Merck-Serono, Merz, Novartis, Teva and Sanofi-Aventis. I have also received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Bayer-Schering Healthcare, Biogen-Idec, Canbex, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, Ironwood, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals.

    JP: Served on an advisory board for Merck Serono

    BJ, NV, AK: none.

Data Availability

Code on Github: https://github.com/benjacobs123456/benjacobs

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 27, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Epidemiology of Epstein-Barr Virus infection and Infectious Mononucleosis in the United Kingdom
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Epidemiology of Epstein-Barr Virus infection and Infectious Mononucleosis in the United Kingdom
Ashvin Kuri, Benjamin Meir Jacobs, Nicola Vickaryous, Julia Pakpoor, Jaap Middeldorp, Gavin Giovannoni, Ruth Dobson
medRxiv 2020.01.21.20018317; doi: https://doi.org/10.1101/2020.01.21.20018317
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Epidemiology of Epstein-Barr Virus infection and Infectious Mononucleosis in the United Kingdom
Ashvin Kuri, Benjamin Meir Jacobs, Nicola Vickaryous, Julia Pakpoor, Jaap Middeldorp, Gavin Giovannoni, Ruth Dobson
medRxiv 2020.01.21.20018317; doi: https://doi.org/10.1101/2020.01.21.20018317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)